EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus

Alina Volkova iD, Victor Sokolov iD, Florencia Tettamanti iD, Meghna Verma iD, Yaroslav Ugolkov iD, Kirill Peskov iD, Weifeng Tang iD, Holly Kimko iD

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Alina Volkova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Modeling and Simulation Decisions FZ - LLC, Dubai, UAE. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Interferon Type I, Inflammation, Models, Biological. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicInterferon Type IInflammationModels, BiologicalHumansAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalInterferon-alpha

Stichwörter der Autor:innen

autoimmune diseaseslupusmathematical modelingquantitative systems pharmacologytype 1 interferon

Substanzen

Antibodies, Monoclonal, HumanizedInterferon Type IanifrolumabAntibodies, MonoclonalsifalimumabInterferon-alpha

Autor:innen und Institutionen

  • Modeling and Simulation Decisions FZ - LLC, Dubai, UAE.
  • Marchuk Institute of Numerical Mathematics of the Russian Academy of Sciences, Moscow, Russia.
  • Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Cambridge, UK.
  • Systems Medicine, Clinical Pharmacology and Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Gaithersburg, Maryland, USA.
  • Research Center of Model-Informed Drug Development, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.

ORCID-Profile: Alina Volkova, Victor Sokolov, Florencia Tettamanti, Meghna Verma, Yaroslav Ugolkov, Kirill Peskov, Weifeng Tang, Holly Kimko

Zitieren

APA

Volkova, A., Sokolov, V., Tettamanti, F., Verma, M., Ugolkov, Y., Peskov, K., Tang, W., & Kimko, H. (2025). An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70043

Vancouver

Volkova A, Sokolov V, Tettamanti F, Verma M, Ugolkov Y, Peskov K, et al. An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70043

BibTeX
@article{Volkova2025,
  author = {Volkova, Alina and Sokolov, Victor and Tettamanti, Florencia and Verma, Meghna and Ugolkov, Yaroslav and Peskov, Kirill and Tang, Weifeng and Kimko, Holly},
  title = {An Integrative Mechanistic Model of Type 1 IFN ‐Mediated Inflammation in Systemic Lupus Erythematosus},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70043}
}
Kostenlos starten →